In this article, we will look at the 14 Stocks Under $5 with Highest Upside Potential.
On October 28, Paul Tudor Jones, Tudor Investment Corporation founder and CIO and Robin Hood Foundation founder and board member, appeared on CNBC’s ‘Squawk Box’ to talk about the latest trends in the market.
Jones stated that the situation feels exactly like 1999 to him, and while he does not know whether the market would replay it exactly, he does believe that all the ingredients are in place. Therefore, according to him, from a trading standpoint, one should position oneself as if it were October 1999. He does not see a reason why anyone would do anything but that, since the Nasdaq doubled between the first week of October 1999 and March 2000.
READ ALSO: 12 Most Undervalued Small Cap Stocks to Invest In Now and 9 Most Profitable Biotech Stocks to Buy.
Jones added that “if it looks like a duck and quacks like a duck, it is probably not a chicken”, and his guess is that all the ingredients are in place for some kind of a “blow off”. History often rhymes, which is why he believes that some version of it will happen again.
With these trends in view, let’s look at the best stocks under $5 with the highest upside potential.
Our Methodology
We used Finviz to compile a list of stocks under $5 that analysts were bullish on and selected the top 14 with the highest analyst upside potential. We also added the number of hedge fund holders as of Q2 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of analyst upside.
Note: All data was recorded on October 29.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
14 Stocks Under $5 with Highest Upside Potential
14. Bit Digital, Inc. (NASDAQ:BTBT)
Analyst Upside: 55.84%
Share Price: $3.85
Number of Hedge Fund Holders: 27
Bit Digital, Inc. (NASDAQ:BTBT) is one of the best stocks under $5 with highest upside potential. On October 29, H.C. Wainwright analyst Kevin Dede maintained a Buy rating on Bit Digital, Inc. (NASDAQ:BTBT). The analyst set a $7 price target, basing the optimistic rating on the company’s growth potential and strategic positioning.
He cited the company’s shift from Bitcoin to Ethereum, stating that Bit Digital, Inc.’s (NASDAQ:BTBT) focus on HPC infrastructure lends it an advantageous position in the evolving crypto and technology landscape.
The CEO of Bit Digital, Inc. (NASDAQ:BTBT) boasts a solid Ethereum background, which positions the company well to effectively manage its Ethereum holdings and staking operations, according to the analyst.
Another key reason supporting Dede’s optimistic rating is Bit Digital, Inc.’s (NASDAQ:BTBT) considerable stake in WhiteFiber, which is involved in HPC-AI cloud and colocation services. WhiteFiber is trading at a discount compared to its peers, and the analyst believes that this undervaluation paves the way for future appreciation as the company’s market cap-to-sales ratio increasingly aligns with industry standards.
Headquartered in New York City, Bit Digital (NASDAQ:BTBT) is a holding company that provides a platform for digital assets and AI infrastructure. Its Bitcoin mining operations are spread through the US, Canada, and Iceland.
13. Stagwell Inc. (NASDAQ:STGW)
Analyst Upside: 69.13%
Share Price: $4.73
Number of Hedge Fund Holders: 15
Stagwell Inc. (NASDAQ:STGW) is one of the best stocks under $5 with highest upside potential. Rosenblatt Securities analyst Barton Crockett reiterated a Buy rating on Stagwell Inc. (NASDAQ:STGW) on October 29 and set a $9 price target on the shares.
The rating update followed Stagwell Inc.’s (NASDAQ:STGW) announcement on October 21 that The Marketing Cloud, which is a part of the Stagwell Network, reported the public launch of Agent Cloud. Agent Cloud is a “secure, unified platform that simplifies access to the world’s leading AI tools and purpose-built marketing assistants,” specifically designed for ease of use, flexibility, and security.
Management reported that Agent Cloud offers agencies and brands instant access to top multimodal LLMs and image/video tools (from GPT-5 to Gemini 2.5 Pro and Veo3), eliminating the “hassle of juggling multiple subscriptions”.
Stagwell Inc. (NASDAQ:STGW) is a global marketing company specializing in performance media and data, digital transformation, creativity and communications, and consumer insights and strategy. The Brand Performance Network segment encompasses creative media consulting, business-to-business marketing capabilities, and more. The Communications Network, in contrast, covers a network offering strategic corporate communications, advocacy, public relations, investor relations, online fundraising, and other services to political and advocacy organizations and corporations.
11. Integra Resources Corp. (NYSE:ITRG)
Analyst Upside: 77.42%
Share Price: $2.75
Number of Hedge Fund Holders: 9
Integra Resources Corp. (NYSE:ITRG) is one of the best stocks under $5 with highest upside potential. Integra Resources Corp. (NYSE:ITRG) received a rating update from Raymond James analyst Brian MacArthur on October 24, who lifted the price target for the stock to C$5.75 from C$5.50 while keeping an Outperform rating on the shares.
The same day, Stifel Nicolaus analyst Ingrid Rico reiterated a Buy rating on the stock, and set a price target of C$7.00.
The rating updates came after Integra Resources Corp. (NYSE:ITRG) announced solid fiscal Q3 2025 gold production results from Florida Canyon Mine on October 23, and lifted quarter-over-quarter cash balance to $81.2 million, marking the strongest ever financial position for the company.
George Salamis, President, CEO and Director of Integra Resources Corp. (NYSE:ITRG), attributed this milestone to strong production results from Florida Canyon and a solid gold price environment, stating that Florida Canyon is delivering on expectations, “generating meaningful cash flow to fund crucial reinvestment into the mine, while also supporting the company’s broader growth strategy”.
The Mine produced 20,653 ounces of gold and sold 20,265 ounces of gold during fiscal Q3 2025, in line with Integra Resources Corp.’s (NYSE:ITRG) expectations.
Integra Resources Corp. (NYSE:ITRG) is a development stage company involved in the acquisition, development, and exploration of mineral properties in the Americas.
11. CytomX Therapeutics, Inc. (NASDAQ:CTMX)
Analyst Upside: 84.05%
Share Price: $3.26
Number of Hedge Fund Holders: 21
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the best stocks under $5 with highest upside potential. On October 28, Oppenheimer analyst Matthew Biegler maintained a Buy rating on CytomX Therapeutics, Inc. (NASDAQ:CTMX) and set a $7 price target.
However, J.P. Morgan analyst Anupam Rama reiterated a Hold rating on the stock on October 23 without assigning a price target.
Rama based the rating on the future potential and current status of CytomX Therapeutics’ CX-2051, stating that he expects more clarity on its safety profile and efficacy from the upcoming Phase 1 data update for CX-2051 in advanced colorectal cancer.
Although the initial data exhibited promising efficacy with a higher objective response rate when compared to standard treatments, the analyst believes that concerns remain about adverse events, especially diarrhea. This could affect the overall safety perception of the drug, supporting the cautious stance.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is a clinical-stage, oncology-focused biopharmaceutical company that develops conditionally activated biologics localized to the tumor microenvironment.
10. BitFuFu Inc. (NASDAQ:FUFU)
Analyst Upside: 87.86%
Share Price: $3.46
Number of Hedge Fund Holders: 9
BitFuFu Inc. (NASDAQ:FUFU) is one of the best stocks under $5 with highest upside potential. On October 27, BitFuFu Inc. (NASDAQ:FUFU) announced the offering of the NTMINER S21+ Hyd. Bitcoin miners for purchase and hosting via the company’s platform, stating that it is offering a special rate of $15.3 per terahash (TH/s) as part of this hosted mining offering.
The hosting fee is as low as $0.078/kWh, offering a “compelling opportunity for miners preparing for the Bitcoin bull market”. Management added that the service is available for customers across the globe, especially in the US.
Manufactured by BITMAIN, the ANTMINER S21+ Hyd. is a high-performance Bitcoin mining machine specially designed for hydro-cooled operations, delivering a hashrate of 358 TH/s at 5370 W, and attaining “an industry-leading energy efficiency of 15 J/TH”.
BitFuFu Inc. (NASDAQ:FUFU) provides digital asset mining and cloud mining services. It functions through an array of stable and intelligent digital asset mining solutions, including one-stop cloud mining services and miner hosting services to individual digital asset enthusiasts and institutional customers. The company also offers a compliant, secure, and transparent blockchain infrastructure.
9. Western Copper and Gold Corporation (NYSE:WRN)
Analyst Upside: 89.13%
Share Price: $2.12
Number of Hedge Fund Holders: 4
Western Copper and Gold Corporation (NYSE:WRN) is one of the best stocks under $5 with highest upside potential. Stifel analyst Ralph Profiti lifted the price target on Western Copper and Gold Corporation (NYSE:WRN) to C$6 from C$5.50 on October 21, maintaining a Buy rating on the stock.
Similarly, H.C. Wainwright analyst Heiko Ihle also maintained a bullish outlook on Western Copper and Gold Corporation (NYSE:WRN) on October 7, maintaining a Buy rating on the shares and raising the price target to $4.25 from $4.00.
Ihle cited the company’s Casino Project, stating that the submission of the Environmental and Socio-economic Effects (ESE) Statement to the Yukon Environmental and Socio-economic Assessment Board (YESAB) was a notable milestone in the permitting process.
He elaborated that the submission entails elaborate environmental management measures, which the analyst anticipates to act as a catalyst for the company’s progress. Ihle added that Western Copper and Gold Corporation (NYSE:WRN) has substantial cash reserves and a solid financial position, supporting the optimistic outlook on the stock.
Western Copper and Gold Corporation (NYSE:WRN) is an exploration-stage company involved in the exploration, acquisition, and future development of mineral resource properties.
8. Opko Health Inc. (NASDAQ:OPK)
Analyst Upside: 106.19%
Share Price: $1.46
Number of Hedge Fund Holders: 18
Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $5 with highest upside potential. ModeX Therapeutics Inc., an Opko Health Inc. (NASDAQ:OPK) company, announced on October 29 a license and collaboration agreement with Regeneron Pharmaceuticals Inc. for the development and discovery of multispecific antibodies for a number of therapeutic indications of mutual interest.
Management reported that the collaboration will “apply ModeX’s MSTAR platform and Regeneron’s proprietary binders to develop multispecific antibody candidates” targeting several distinct biological pathways in a single molecule.
The terms of the agreement dictate that ModeX would receive an “upfront payment of USD $7 million, and potential future product selection payments, clinical and regulatory milestone payments, and commercial milestone payments exceeding USD $200 million per selected molecule”.
The collaboration’s overall value potentially surpasses $1 billion “if multiple products from the collaboration are successful”. Additionally, ModeX is “eligible to receive tiered global net sales royalties, up to low double digits at the highest tier”. Regeneron Pharmaceuticals Inc. would lead and fund any clinical, preclinical, and commercialization activities for the products it elects to advance.
Opko Health Inc. (NASDAQ:OPK) is a biopharmaceutical and diagnostics company that provides healthcare services. Its operations are divided into the Diagnostics and Pharmaceuticals segments.
7. Canaan Inc. (NASDAQ:CAN)
Analyst Upside: 113.52%
Share Price: $1.41
Number of Hedge Fund Holders: 9
Canaan Inc. (NASDAQ:CAN) is one of the best stocks under $5 with highest upside potential. Canaan Inc. (NASDAQ:CAN) announced on October 28 the official launch of its latest generation bitcoin mining machine, the Avalon A16 series (the A16) at the Blockchain Life 2025 summit in Dubai, marking a considerable advancement in mining performance and chip innovation.
Management reported that the newly launched Avalon A16XP air-cooled model (the A16XP) delivers “300 terahash per second (TH/s) of computing power per unit at a power efficiency of 12.8 joules per terahash (J/TH)”. The A16XP is one of the most competitive mining machines in the market at present, equipped with “Avalon’s superior durability and reliability”. It empowers mining clients to “maintain operational advantage and maximize return on investment, even amid rising network difficulty”.
Canaan Inc. (NASDAQ:CAN) added that with the advancement of this strategic model, the company is well-positioned to “capture greater value throughout industry cycles”, while simultaneously enhancing resiliency, efficiency, and operational agility.
Canaan Inc. (NASDAQ:CAN) is a holding company that develops and sells Bitcoin mining machines and related services. It specializes in green mining. The company also designs, researches, and sells Integrated circuits (IC) and leases mining equipment by integrating IC products for Bitcoin mining and related components in China.
6. Alight Inc. (NYSE:ALIT)
Analyst Upside: 136.49%
Share Price: $2.96
Number of Hedge Fund Holders: 30
Alight Inc. (NYSE:ALIT) is one of the best stocks under $5 with highest upside potential. Alight Inc. (NYSE:ALIT) announced on October 28 the introduction of the limited release of its “new generative AI-driven solution on Alight Worklife® for benefits enrollment optimization and benefits utilization” during the 2025 annual enrollment season. It reported that the new tool expands upon the company’s present AI capabilities by “integrating user-driven data to power personalized guidance throughout an employee’s benefits enrollment journey”.
Lenny Fayard, Senior Vice President of Product Strategy and AI at Alight Inc. (NYSE:ALIT), stated that “by harnessing the power of AI, employees can more easily navigate their options and make more informed, confident decisions, while employers can have peace of mind helping their people choose the benefits that best meet their needs.”
Separately, Needham analyst Kyle Peterson reiterated a Buy rating on Alight Inc. (NYSE:ALIT) on October 20, setting a price target of $4.50. While Citi also maintained a Buy rating on the stock on October 10, it lowered the price target to $8.50 from $11, telling investors that the company remains confident in its margin expansion.
Headquartered in Chicago, IL, Alight Inc. (NYSE:ALIT) provides cloud-based integrated digital human capital and business solutions.
5. Aurora Innovation, Inc. (NASDAQ:AUR)
Analyst Upside: 141.69%
Share Price: $4.96
Number of Hedge Fund Holders: 41
Aurora Innovation, Inc. (NASDAQ:AUR) is one of the best stocks under $5 with highest upside potential. Needham analyst Chris Pierce maintained a Buy rating on Aurora Innovation, Inc. (NASDAQ:AUR) on October 29, setting a price target of $13.
The analyst based the positive rating on the company’s promising future, stating that Aurora Innovation, Inc. (NASDAQ:AUR) delineated a clear pathway for the attainment of its 2026 and 2027 goals. The company has a special focus on autonomous operations, and has bolstered its position by providing an updated timeline for driver-out autonomous operations.
While some concerns exist regarding reliance on third-party OEM trucks, the analyst believes that the company is working towards meeting the demand of the logistics industry and accumulating real-world miles. It is also making notable progress by meeting milestones according to planned timelines, including advancing lane expansion to El Paso.
Aurora Innovation, Inc. (NASDAQ:AUR) designs and develops automobile software and hardware, and provides data services. The company also offers the Aurora Driver, an innovative self-driving freight technology that allows a vehicle to drive itself.
4. Savara Inc. (NASDAQ:SVRA)
Analyst Upside: 143.49%
Share Price: $4.42
Number of Hedge Fund Holders: 18
Savara Inc. (NASDAQ:SVRA) is one of the best stocks under $5 with highest upside potential. On October 23, Citizens JMP lifted its price target on Savara Inc. (NASDAQ:SVRA) to $11 from $8 while keeping an Outperform rating on the shares.
The firm told investors in a research note that its pulmonologist survey shows solid demand for Molbreevi, with 60% of those surveyed expressing an inclination to use it. This, according to Citizens JMP, should mean blockbuster sales, with Savara Inc. (NASDAQ:SVRA) set to resubmit its application for Molbreevi in December.
Additionally, Savara Inc. (NASDAQ:SVRA) was initiated with a new Buy rating by LifeSci Capital analyst Francois Brisebois on October 14, who also based the optimistic outlook on Molbreevi’s promising potential. It is focused on the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare and chronic disease that currently does not have approved treatments in the EU and US, with the sole exception of whole lung lavage.
The analyst thus stated that expert feedback shows that Molbreevi can attain blockbuster status in the US market, with its unique formulation as a large inhaled biologic shielding it from competition from biosimilars.
Savara Inc. (NASDAQ:SVRA) is a clinical-stage pharmaceutical company that develops and commercializes novel therapies for serious or life-threatening rare respiratory diseases. The company’s program includes molgramostim, an inhaled formulation of recombinant human GM-CSF being developed to treat autoimmune pulmonary alveolar proteinosis.
3. Compass Therapeutics Inc. (NASDAQ:CMPX)
Analyst Upside: 151.26%
Share Price: $3.98
Number of Hedge Fund Holders: 15
Compass Therapeutics Inc. (NASDAQ:CMPX) is one of the best stocks under $5 with highest upside potential. Compass Therapeutics Inc. (NASDAQ:CMPX) received a rating update from Piper Sandler analyst Biren Amin on October 27, who maintained a Buy rating on the stock with a $12 price target.
Similarly, LifeSci Capital analyst Charles Zhu also expressed bullish sentiments for Compass Therapeutics Inc. (NASDAQ:CMPX) on October 17, reiterating a Buy rating with a $10 price target.
Zhu cited the promising progress of the company’s COMPANION-002 trial, which is testing tovecimig for second-line biliary tract cancer (BTC) patients. The trial exhibited potential clinical benefits with a median follow-up of around 19 months, which the analyst considers notable since it exceeds the overall survival rates shown by other similar studies.
In addition to this positive outlook for the treatment, Zhu expects the anticipated pricing strategy for tovecimig to offer financial upside, with both domestically and internationally ongoing regulatory engagements further expected to bolster future growth prospects.
Compass Therapeutics Inc. (NASDAQ:CMPX) is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics. The company’s platform includes human display for antibody tuning, common light chain-focused antibody discovery, stitchmabs, and highly modular and manufacturable bispecific candidates.
2. Neumora Therapeutics, Inc. (NASDAQ:NMRA)
Analyst Upside: 153.91%
Share Price: $2.56
Number of Hedge Fund Holders: 18
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the best stocks under $5 with highest upside potential. On October 28, Needham lifted its price target on Neumora Therapeutics, Inc. (NASDAQ:NMRA) to $8 from $6 while keeping a Buy rating on the stock. The firm told investors that it is more optimistic about the company’s outlook after its R&D Investor Event that exhibited its broad pipeline.
Similarly, Guggenheim upgraded Neumora Therapeutics, Inc. (NASDAQ:NMRA) to Buy from Neutral on October 27, setting a $14 price target on the shares. The firm told investors that it released the rating update after the “compelling” preclinical obesity data reported by Neumora Therapeutics, Inc. (NASDAQ:NMRA). Guggenheim added that it believes the company’s NLRP3i program in obesity and related disorders to be “a clear driver to value creation.”
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a clinical-stage biotechnology company that integrates neuroscience and data science to offer a precision medicine approach for brain diseases. Its focus is on advancing medicines for therapeutically relevant targets implicated in CNS diseases.
1. Autolus Therapeutics plc (NASDAQ:AUTL)
Analyst Upside: 571.14%
Share Price: $1.49
Number of Hedge Fund Holders: 16
Autolus Therapeutics plc (NASDAQ:AUTL) is one of the best stocks under $5 with highest upside potential. Autolus Therapeutics plc (NASDAQ:AUTL) received a Buy rating from Needham analyst Gil Blum on October 27, who set a $10 price target on the stock and based the optimistic outlook on the company’s promising clinical data.
The rating update came the same day Autolus Therapeutics plc (NASDAQ:AUTL) presented clinical data updates at the American College of Rheumatology Convergence 2025, reporting that “data from Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS, with 50 million cell dose selected for Phase 2 pivotal study.”
The company also reported that the preliminary efficacy data exhibited attainment of the definition of remission in SLE (DORIS) in 83% of patients, along with complete renal response (CRR) in 50% of patients. It added that all remissions and responses are ongoing with no “evidence of disease activity at a median follow-up of 8.9 months.”
Autolus Therapeutics plc (NASDAQ:AUTL) is on track to dose the first patient in the Phase 2 trial in lupus nephritis (LN) by the end of the year. Management reported that Dr. Maria Leandro, consultant rheumatologist at UCL Hospitals and senior lecturer at University College London, stated:
“Data from the CARLYSLE study shows that obe-cel has the potential to make a meaningful clinical impact in patients with severe refractory SLE who are currently without approved treatment options. We observe durable responses in up to 12 months of follow-up and an encouraging safety profile in this difficult to treat patient population. All patients were able to reduce glucocorticosteroids to physiological levels, and responses, including kidney responses, occur early and are durable.”
Autolus Therapeutics (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company based in the United Kingdom. It develops programmed T cell therapies for treating autoimmune diseases and cancer, and focuses on chimeric antigen receptor (CAR) T cell therapy. The company engineers controlled, targeted, and highly active T cell therapy product candidates designed to recognize target cells, break their defense mechanisms down, and eliminate them. It is doing so using a portfolio of proprietary and modular T-cell programming technologies.
While we acknowledge the potential of AUTL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AUTL and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
